13.38

0.07% -0.010

Alto Neuroscience Inc (ANRO)

Overview News Price History Discussions Forecast

Alto Neuroscience Inc stock is traded at $13.38, with a volume of 241.93K. It is down -0.07% in the last 24 hours and up +19.15% over the past month. Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Previous Close:

$13.39

Open:

$13.5

24h Volume:

241.93K

Relative Volume:

0.16

Market Cap:

$415.67M

Revenue:

Net Income/Loss:

$-49.81M

P/E Ratio:

-6.2059

EPS:

-2.156

Net Cash Flow:

$-42.93M

1W Performance:

-0.96%

1M Performance:

+19.15%

6M Performance:

+446.12%

1Y Performance:

+221.63%

1-Day Range:

$13.21

$13.62

1-Week Range:

$12.63

$14.08

52-Week Range:

$1.60

$16.49

Alto Neuroscience Inc Stock (ANRO) Company Profile

Name

Alto Neuroscience Inc

Sector

Healthcare (1131)

Industry

Biotechnology (632)

Phone

773-255-5012

Address

650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW

Employee

Twitter

Next Earnings Date

Latest SEC Filings

ANRO's Discussions on Twitter

Compare ANRO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANRO Alto Neuroscience Inc	13.38	415.98M	0	-49.81M	-42.93M	-2.156
VRTX Vertex Pharmaceuticals Inc	457.26	117.50B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	722.83	76.06B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	464.56	62.53B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	916.31	56.75B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	205.04	44.10B	447.02M	-1.18B	-906.14M	-6.1812

Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-17-25	Initiated	BTIG Research	Buy
Sep-29-25	Initiated	Chardan Capital Markets	Buy
Oct-23-24	Downgrade	Rodman & Renshaw	Buy → Neutral
Oct-23-24	Downgrade	Wedbush	Outperform → Neutral
Sep-03-24	Initiated	Wedbush	Outperform
Feb-27-24	Initiated	Jefferies	Buy
Feb-27-24	Initiated	Robert W. Baird	Outperform
Feb-27-24	Initiated	Stifel	Buy
Feb-27-24	Initiated	TD Cowen	Outperform
Feb-27-24	Initiated	William Blair	Outperform

View All

Alto Neuroscience Inc Stock (ANRO) Latest News

Dec 04, 2025

What insider purchases suggest about Alto Neuroscience Inc. stockQuarterly Portfolio Report & AI Enhanced Trade Execution Alerts - Newser

Dec 04, 2025

Will Alto Neuroscience Inc. stock announce special dividendQuarterly Earnings Summary & Community Consensus Stock Picks - Newser

Dec 04, 2025

Can Alto Neuroscience Inc. stock maintain growth trajectoryJuly 2025 Action & Daily Growth Stock Investment Tips - Newser

Dec 04, 2025

Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08December 3, 2025 - BioSpace

Dec 04, 2025

Is Alto Neuroscience Inc. stock undervalued after correctionTrade Volume Summary & Long-Term Growth Plans - Newser

Dec 04, 2025

Can Alto Neuroscience Inc. stock double in next 5 yearsMarket Activity Report & Safe Investment Capital Preservation Plans - Newser

Dec 04, 2025

Dec 03, 2025

What technical patterns form on Alto Neuroscience Inc. stock chartsPortfolio Performance Summary & Step-by-Step Swing Trade Plans - Newser

Dec 03, 2025

Is Alto Neuroscience Inc. stock safe for risk averse investorsQuarterly Profit Report & AI Driven Price Forecasts - Newser

Dec 03, 2025

What dividend safety rating applies to Alto Neuroscience Inc. stockJuly 2025 PreEarnings & Real-Time Buy Zone Alerts - Newser

Dec 03, 2025

What sentiment indicators say about Alto Neuroscience Inc. stock - Newser

Dec 03, 2025

Dec 02, 2025

Short Covering: Why Alto Neuroscience Inc. stock remains undervaluedJuly 2025 Action & Advanced Technical Signal Analysis - BỘ NỘI VỤ

Dec 02, 2025

Can Alto Neuroscience Inc. stock test all time highsLayoff News & Risk Controlled Stock Pick Alerts - Newser

Dec 02, 2025

Is Alto Neuroscience Inc. stock a buy during volatile markets2025 Key Lessons & Expert Approved Momentum Trade Ideas - Newser

Dec 02, 2025

How strong dollar benefits Alto Neuroscience Inc. stockJuly 2025 Review & Risk Controlled Stock Alerts - Newser

Dec 02, 2025

Dec 01, 2025

Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire

Dec 01, 2025

Biotech Co.'s Q3/25 Progress on Lead Programs Steady - streetwisereports.com

Dec 01, 2025

Biotech Co. Advances Precision Psychiatry Breakthrough Pipeline While Analysts' Sentiment Remains Positive - streetwisereports.com

Dec 01, 2025

Lost Money on Alto Neuroscience, Inc. (ANRO)? Contact Levi & Kors - The National Law Review

Dec 01, 2025

Nov 30, 2025

ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review

Nov 30, 2025

Nov 28, 2025

Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026 (NYSE:ANRO) - Seeking Alpha

Nov 28, 2025

Alto Neuroscience files to sell 8.45M shares of common stock for holders - TipRanks

Nov 28, 2025

Nov 26, 2025

Alto Neuroscience (NYSE: ANRO) files to register 8,454,514 resale shares from $50M private placement - Stock Titan

Nov 26, 2025

Nov 24, 2025

Alto Neuroscience’s ALTO-101 Study: A Potential Game-Changer for Schizophrenia Treatment? - MSN

Nov 24, 2025

Nov 21, 2025